Kaori Terata

Dr. Kaori Terata


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2021 in International Cancer Conference Journal
Verified
Journal Article
Open access
PDF file
ETEriko Takahashi
Eriko Takahashi
KTKaori Terata
Kaori Terata
HNHiroshi Nanjo
Hiroshi Nanjo
KIKoichi Ishiyama
Koichi Ishiyama
YHYuko Hiroshima
Yuko Hiroshima
YMYoshihiro Minamiya
Yoshihiro Minamiya
We herein report on a male with primary accessory breast cancer in an axilla. A 75-year-old man first noticed a subcutaneous nodule about 2 cm in diameter in the area of his right axilla. The patient underwent extirpation of the mass in a public hospital. Histological examination revealed invasive breast carcinoma of no special type associated with mucinous carcinoma, invasive micropapillary carcinoma and intraductal components. Immunohistochemical analysis showed that the tumor cells were positive for Gross cystic disease fluid protein (GCDFP)-15, mammaglobin and GATA3. Staining for estrogen receptor (ER) and progesterone receptor (PR) was positive, and human epidermal growth factor receptor 2 (HER2) was negative. The Ki67 labeling index (LI) was 33.6%. Imaging revealed no evidence of a primary tumor in any other organ or in the bilateral mammary gland. We performed radical resection of the right axilla, including the scar, and axillary lymph node dissection. The final pathological examination of the surgical specimen showed normal mammary gland tissue that was not connected to the proper mammary gland, and no residual cancer or metastatic lymph nodes. Based on our clinical and pathological findings, this tumor was diagnosed as breast cancer originating from the accessory mammary gland in the right axilla. After surgery, tamoxifen was administered as adjuvant therapy. Since the surgery, 2 years ago, there has been no evidence of recurrence. Hereditary Breast and Ovarian Cancer syndrome was suspected in this case because the patient was a male with breast cancer, and he had two first-degree relatives with breast cancer. This patient had no BRCA mutations on genetic testing. Nonetheless, in cases of male breast cancer, it is necessary to obtain genetic information due to the possibility of hereditary breast cancer, including cancers associated with BRCA gene mutation.

1 August 2020 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
KTKaori Terata
Kaori Terata
KIKazuhiro Imai
Kazuhiro Imai
AWAkiyuki Wakita
Akiyuki Wakita
YSYusuke Sato
Yusuke Sato
SMSatoru Motoyama
Satoru Motoyama
YMYoshihiro Minamiya
Yoshihiro Minamiya
Breast cancer is the most commonly diagnosed cancer in females worldwide. If diagnosed early, patients generally have good outcomes. However, approximately 20% to 30% of all women diagnosed with breast cancer develop metastatic disease. Metastatic breast cancer is incurable, but there is growing evidence that resection or other local therapy for breast cancer liver metastases (BCLM) may improve survival. We aimed to review indications for and outcomes of perioperative liver resection and other local therapies for BCLM. In this series, we reviewed 11 articles (605 patients) focusing on surgical resection and 7 articles (266 patients) describing radiofrequency ablation (RFA) for BCLM. Median disease-free survival (DFS) after surgical resection was 23 months (range, 14–29 months) and median overall survival (OS) was 39.5 months (range, 26–82 months). One, 3- and 5-year survivals were 89.5%, 70%, and 38%, respectively. The factors favoring better outcomes are hormone receptor positive primary breast cancer status, R0 resection, no extrahepatic metastases (EHM), small BCLM, and solitary liver metastases. On the other hand, the median DFS with RFA was 11 months, median OS was 32 months, and the 3- and 5-year OS were 43% and 27%, respectively. The clinical features that are indications for RFA are smaller tumor and higher EHM rate than those favoring surgical resection (2.4 vs. 4.0 cm and 46% vs. 27%). The merits of RFA are its high technical success rate, low morbidity, short hospital stay, and that it can be repeated. Although results are as yet limited, in carefully selected patients, resection or other local therapies such as RFA, render BCLM potentially provide prognostic improvement.

1 August 2020 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
KTKaori Terata
Kaori Terata
AYAyuko Yamaguchi
Ayuko Yamaguchi
AIAyano Ibonai
Ayano Ibonai
KIKazuhiro Imai
Kazuhiro Imai
AWAkiyuki Wakita
Akiyuki Wakita
YMYoshihiro Minamiya
Yoshihiro Minamiya
Advances have been made in systemic as well as locoregional treatment of primary breast cancer. Evidence, based established therapeutic strategies, for isolated locoregional lymph node recurrence is not yet sufficient. In this series, we focused especially on isolated axillary lymph node recurrence (AR) and supraclavicular lymph node recurrence (SR) in patients receiving systemic and/or radiation therapy combined with surgery. Disease free survival (DFS) in patients with AR ranged from 20 to 36 months. From 69% to 77% of all patients underwent surgical excision. The 5-year overall survival (OS) ranged from 39% to 46%. Positive lymph node metastases of primary cancer, size of the primary tumor, and R0 resection were associated with good outcomes. Longer DFS is associated with good outcomes. Limited SR data showed DFS to range from 25–27%. Median progression free survival (PFS) was 18 months, 5-year OS rates were 24–42%, and 5-year OS were 29–34 months. Combination therapy was an independent factor associated with better PFS as compared to local therapy only. Salvage treatment and grade of the primary tumor significantly were associated with OS on multivariate analysis. Available data, retrospective and not randomized, showed therapy combining systemic treatments and/or radiotherapy with surgery might contribute to good local control, better PFS, and longer OS.

23 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CKChiaki Kudo
Chiaki Kudo
KTKaori Terata
Kaori Terata
HNHIROSHI NANJO
HIROSHI NANJO
Kyoko NOMURAKyoko NOMURA
Kyoko NOMURA
HYHIROSHIMA YUKO
HIROSHIMA YUKO
KIKAZUHIRO IMAI
KAZUHIRO IMAI
Background: Immunohistochemistry (IHC) is crucial for determining cancer treatments. We previously developed a rapid IHC method and have now developed a fully automated rapid IHC stainer (R-Auto). This study aimed to evaluate the clinical reliability of the R-Auto protocol for staining estrogen receptors (ERs) in breast cancer specimens and evaluate the staining performance. Methods: Between January 2015 and June 2020, 188 surgical specimens collected from breast cancer patients treated at our hospital were evaluated via ER staining using R-Auto, conventional manual IHC, and a commercial autostainer. The specimens were scored using Allred scores, after which the staining results were compared between R-Auto and conventional IHC or the commercial autostainer. Weighted kappa coefficients and AC1 statistics were used to assess the agreement between the methods. Results: The AC1 statistic for comparison between R-Auto and conventional IHC was 0.9490 (0.9139–0.9841), with a 95.7% agreement rate, and that for comparison between R-Auto and the commercial autostainer was 0.9095 (0.8620–0.9570), with a 92.6% agreement. There was, thus, substantial agreement between R-Auto and both conventional IHC and the commercial autostainer. However, R-Auto shortened the time required for IHC from 209 min with conventional IHC to 121 min. Conclusions: R-Auto enables a good staining performance in a shorter time with less effort.

31 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
CKChiaki Kudo
Chiaki Kudo
KTKaori Terata
Kaori Terata
HNHIROSHI NANJO
HIROSHI NANJO
Kyoko NOMURAKyoko NOMURA
Kyoko NOMURA
HYHIROSHIMA YUKO
HIROSHIMA YUKO
KIKAZUHIRO IMAI
KAZUHIRO IMAI
Background: Immunohistochemistry (IHC) is crucial for determining cancer treatments. We previously developed a rapid IHC method and have now developed a fully automated rapid IHC stainer (R-Auto). The aim of this study was to evaluate the clinical reliability of the R-Auto protocol for staining estrogen receptors (ERs) in breast cancer specimens and evaluated the staining performance. Methods: Between January 2015 and June 2020, 188 surgical specimens collected from breast cancer patients treated at our hospital were evaluated through ER staining using R-Auto, conventional manual (conventional) IHC and a commercial autostainer. The specimens were scored using Allred scores, after which the staining results were compared between R-Auto and the conventional IHC or commercial autostainer. Weighted kappa coefficients and AC1 statistics were used to assess the agreement between methods. Results: The AC1 statistic for comparison between R-Auto and conventional IHC was 0.9490 (0.9139-0.9841) with a 95.7% agreement rate and was 0.9095 (0.8620-0.9570) with a 92.6% agreement rate for comparison between R-Auto and the commercial autostainer. There was thus substantial agreement between R-Auto and both conventional IHC and the commercial autostainer. However, R-Auto shortened the time required for IHC from 209 minutes with conventional IHC to 121 minutes. Conclusions: R-Auto enables good staining performance in a shorter time with less effort.